

RECEIVED
OPPT NOIC

MERCAPTANS/THIOLS COUNCIL

17260 Vannes Court, Hamilton, VA 20158

Office (540) 751-2093 ■ Fax (540) 751-2094 ■ ehunt@adelphia.net

86HQ-0805-16159

August 17, 2005
Submitted via Fedex

Contain NO CBI

TSCA Confidential Business Information Center (7407M)
EPA East - Room 6428 Attn: Section 8(e)
U.S. Environmental Protection Agency
1201 Pennsylvania Avenue, NW
Washington, DC 20460-0001



Re: TSCA Section 8(e) Submission
Sodium Mercaptide (CAS No. 5188-07-8)

Dear Sir/Madam:

This submission is being made on behalf of the Mercaptans/Thiols Council to the United States Environmental Protection Agency (USEPA) pursuant to Section 8(e) of the Toxic Substances Control Act (TSCA). A recently received draft report provides preliminary data from a Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in Rats (OECD 421) with Sodium Mercaptide (CAS Number 5188-07-8; Sodium MESH). This research was sponsored under the International Council of Chemical Associations' (ICCA) Program as part of a category approach.

In this study, rats were exposed by oral gavage to 0, 5, 15 and 45 mg/kg/day Sodium MESH. Below is a list of the effects observed in the 45 mg/kg/day dose group.

- Hypotonia was transiently observed in all males and females during the whole dosing period.
- Ptyalism was observed in most males and females a few days after initiation of dosing until the end of dosing.
- Blood effects were noted - lowered hemoglobin concentration (male and female), lower mean cell volume (male), lower mean cell hemoglobin concentration (female), lower red blood cell count (female), lower packed cell volume (female).
- Increased incidence and/or severity of extramedullary hematopoiesis in the spleen (male and female) and liver (female).
- Increased incidence and/or severity of hemosiderosis in the spleen (male and female).



288480


TSCA Section 8(e)
5188-07-8
August ??, 2005

No adverse effects were noted in the 5 and 15 mg/kg dose groups. No reproductive or developmental effects were noted in any group.

This submission is being made on behalf of the following members of the Mercaptans/Thiols Council who are the producers of Sodium Methyl Mercaptide: Arkema Inc. and Chevron Phillips Chemical Company LP. The parties of this international consortium assert that this notice does not involve effects in humans and nothing in this letter is considered confidential business information [CBI] by the Mercaptans/Thiols Council or its members.

If you have any questions regarding this submission please contact me at (540) 751-2093 or via e-mail at ehunt@adelphia.net.

Sincerely,

A handwritten signature in black ink, appearing to read 'Elizabeth K. Hunt', written over the word 'Sincerely,'.

Elizabeth K. Hunt
Executive Director
Mercaptans/Thiols Council